E-resources
Peer reviewed
Open access
-
Lazzaroni, Elisa; Lunati, Maria Elena; Montefusco, Laura; Pastore, Ida; Chebat, Enrica; Cimino, Vincenzo; Morpurgo, Paola Silvia; Muratori, Milena; Plebani, Laura; Bolla, Andrea; Rossi, Antonio; Vallone, Luciana; Gandolfi, Alessandra; Tinari, Camilla; D’Addio, Francesca; Nasr, Moufida Ben; Loretelli, Cristian; Scaranna, Cristiana; Bellante, Rosalia; Manfrini, Roberto; Muratori, Fabrizio; Franzetti, Ivano; Orsi, Emanuela; Gazzaruso, Carmine; Ghelardi, Renata; Desenzani, Paolo; Genovese, Stefano; Girelli, Angela; Folli, Franco; Berra, Cesare; Fiorina, Paolo
Pharmacological research, September 2022, 2022-09-00, 20220901, 2022-09-01, Volume: 183Journal Article
Dapagliflozin has been demonstrated to improve glycemic control, blood pressure, and body weight in type 2 diabetes mellitus (T2D); indeed, it can also reduce the risk of progression to renal failure, of hospitalization for heart failure and of cardiovascular death. We aim to investigate the acute effect of Dapagliflozin on kidney function in the common clinical practice in T2D. This is a study including 1402 patients with T2D recruited from 11 centers in Lombardia, Italy, who were evaluated at baseline and after 6 months of treatment with Dapagliflozin 10 mg per day. The primary outcome of the study was the change in HbA1c, while the secondary outcomes were modification of weight, BMI, systolic and diastolic pressure, creatinine, eGFR and albuminuria status. After 24 weeks of treatment with Dapagliflozin, a reduction in Hb1Ac was observed (−0.6 ± 1.8%) as well as in BMI (−1.5 ± 5.2 kg/m2). Statistically significant changes were also found for systolic and diastolic blood pressure, cholesterol and triglycerides. Interestingly, a statistically significant acute improvement of kidney function was evident. Our analyses confirm the beneficial effects of dapagliflozin after 6 months of therapy, with improvements of glycemic and lipid profiles, blood pressure, BMI. Finally, an acute positive effect on albuminuria and KIDGO classes was observed during a 6 months treatment with dapagliflozin in patients with T2D. Display omitted
Author
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
If the library membership card is not in the list,
add a new one.
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|
Source: Personal bibliographies
and: SICRIS
The material is available in full text. If you wish to order the material anyway, click the Continue button.